| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G/A |
| 29 Oct 2026 | DEFA14A |
| 29 Oct 2026 |
Proxy statement: annual meeting on December 10, 2026
CEO pay $584K, down 50% · say-on-pay vote |
| 29 Oct 2026 | 10-Q |
| 15 Sep 2026 | SCHEDULE 13D/A |
| 14 Sep 2026 |
Form 4: Duhay Francis, Director
Sold 11 shares ($123) |
| 11 Sep 2026 | 144 |
| 21 Aug 2026 | S-3 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 30 Jul 2026 | 10-Q |
| 14 Jul 2026 |
8-K: Regulation FD Disclosure
On July 14, 2026, enVVeno Medical Corporation (the “Company”) issued an investor presentation, which may be used by the Company, including at meetings with investors, analysts or others, in whole or in part and possibly with modification... |
| 12 Jun 2026 |
Form 4: Duhay Francis, Director
Sold 140 shares ($1.44K) |
| 11 Jun 2026 | 144 |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 06 May 2026 | 10-Q |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial |
| 26 Mar 2026 | S-8 |
| 26 Mar 2026 | 10-K |
| 13 Mar 2026 |
Form 4: Duhay Francis, Director
Sold 140 shares ($1.61K) |
Loading...